Orchid Pharma Ltd. saw a 4% jump in its stock price following the successful completion of a surprise inspection by the United States Food and Drug Administration (USFDA) at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. As of 9:59 AM, the shares were trading 4.45% higher at Rs 865.15.
Conducted between February 10-18, 2025, the inspection concluded with seven minor observations, none related to data integrity concerns, reinforcing Orchid Pharma’s strong regulatory compliance.
The company continues to maintain its position as India’s only USFDA-approved facility for Sterile Cephalosporins, a critical class of antibiotics. This achievement further solidifies Orchid Pharma’s reputation in the global pharmaceutical market, ensuring uninterrupted supply to key international markets, including the U.S.
In addition to the USFDA approval, Orchid Pharma also secured the renewal of its EU Good Manufacturing Practice (GMP) certification, demonstrating its adherence to stringent European regulatory standards.
Orchid Pharma’s stock opened at ₹837.00 today, reaching a high of ₹874.55 and a low of ₹824.25. The share price remains close to its 52-week low of ₹800.00, significantly lower than its 52-week high of ₹1,997.40.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
